Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 226 AL 240

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. doi: 10.2174/156720511796717122.

Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies

Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R.

Curr Alzheimer Res. 2011 Sep;8(6):659-65. doi: 10.2174/156720511796717177.

C-Abl tyrosine kinase signaling: a new player in AD tau pathology

Estrada LD, Zanlungo SM, Alvarez AR.

Curr Alzheimer Res. 2011 Sep;8(6):643-51. doi: 10.2174/156720511796717249.

A novel perspective on tau in Alzheimer's disease

Bonda DJ, Castellani RJ, Zhu X, Nunomura A, Lee HG, Perry G, Smith MA.

Curr Alzheimer Res. 2011 Sep;8(6):639-42. doi: 10.2174/156720511796717131.

Role of protein phosphatase 2A in Alzheimer's disease

Rudrabhatla P, Pant HC.

Curr Alzheimer Res. 2011 Sep;8(6):623-32. doi: 10.2174/156720511796717168.

Pin1: a new outlook in Alzheimer's disease

Lonati E, Masserini M, Bulbarelli A.

Curr Alzheimer Res. 2011 Sep;8(6):615-22. doi: 10.2174/156720511796717140.

Mechanisms of tau self-aggregation and neurotoxicity

Farías G, Cornejo A, Jiménez J, Guzmán L, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):608-14. doi: 10.2174/156720511796717258.

Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers

Calon F.

Curr Alzheimer Res. 2011 Aug;8(5):470-8. doi: 10.2174/156720511796391881.

Nutritional approaches to modulate oxidative stress in Alzheimer's disease

Pocernich CB, Lange ML, Sultana R, Butterfield DA.

Curr Alzheimer Res. 2011 Aug;8(5):452-69. doi: 10.2174/156720511796391908.

Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype

Barberger-Gateau P, Samieri C, Féart C, Plourde M.

Curr Alzheimer Res. 2011 Aug;8(5):479-91. doi: 10.2174/156720511796391926.

The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms

Subaiea GM, Alansi BH, Serra DA, Alwan M, Zawia NH.

Curr Alzheimer Res. 2011 Dec;8(8):860-7. doi: 10.2174/156720511798192691.

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial

Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B.

J Alzheimers Dis. 2011;26(2):211-20. doi: 10.3233/JAD-2011-110134.

Tower of London test: a comparison between conventional statistic approach and modelling based on artificial neural network in differentiating fronto-temporal dementia from Alzheimer's disease

Franceschi M, Caffarra P, Savarè R, Cerutti R, Grossi E; Tol Research Group.

Behav Neurol. 2011;24(2):149-58. doi: 10.3233/BEN-2011-0327.

Diagnostic criteria for depression in Alzheimer disease: a study of symptom patterns using latent class analysis

Starkstein SE, Dragovic M, Jorge R, Brockman S, Robinson RG.

Am J Geriatr Psychiatry. 2011 Jun;19(6):551-8. doi: 10.1097/JGP.0b013e3181ec897f.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias